Albany, NY -- (SBWIRE) -- 12/15/2017 -- According to the research report, the global erythropoietin drugs market is expected to be worth US$19,379.2 mn by the end of 2025 as it surges at CAGR of 7.5% from 2017 to 2025.

The Global Erythropoietin Drugs Market is segmented on the basis of Drug Class, Drug Type, Drug Application, Drug Application and Geography.

On the basis of drug class, the market has been segmented into epoetin alfa, epoetin beta, darbepoetin alfa, others. Epoetin alfa was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues. Epoetin alfa is usually related with cancer chemotherapy and chronic renal failure. Rising the prevalence of cancer worldwide according to National institute of cancer, 1,685,210 new cases of cancer estimated in year 2016. On the basis of drug application, the market has been segmented into cancer, renal disease, hematology, neurology, others (surgery, wound healing, etc.). Cancer was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues, owing to the factors such as increasing prevalence of chronic diseases globally.

Read Report Overview @ https://www.transparencymarketresearch.com/erythropoietin-market.html

Based on drug type, the market has been segmented into biologics and biosimilars. The biologic erythropoietin drugs dominated the market in 2016 and are anticipated to remain dominant in the forecast period. This segment is anticipated to grow at a high CAGR during the forecast period owing to long drug exclusivity period, which provides manufacturers a high return on investment (ROI). On the basis of distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2016 and is anticipated to remain the dominant segment in terms of revenues in the forecast period. The online pharmacy segment is anticipated to grow at a significant high CAGR during the forecast period, owing to the factors such as increasing reach of online pharmacy to the customers, rising the internet facilities globally, and other services such as cost containment offered by online pharmacy.

Geographically, the market has been segmented into five regions, including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was the dominant region in terms of revenues in 2016 and is anticipated to remain dominant in the forecast period. The growth in the region can be attributed to the increasing approvals of erythropoietin drugs, government incentives offered for research on chronic disease such as research and development grants, drug exclusivity, tax credit and fee waivers, among others.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1856

Europe is anticipated to be the trailing next in terms of revenues in the forecast period. This growth can be attributed to the increasing prevalence of chronic diseases in the region. Growth of the segment is led by government initiatives for cancer and other chronic disease treatment. Governments of various countries in the region are taking efforts to decrease the rate of incidence of cancer. Asia Pacific region is growing with highest CAGR value. High incidence rate of hematological diseases in countries such as India, China, Bangladesh, and Pakistan is driving the erythropoietin drugs market in Asia Pacific.

Summary of Table of Content

1 Preface
2 Assumptions and Research Methodology
3 Executive Summary
4 Market Overview
5 Global Erythropoietin Drugs Market Analysis, by Drug Class
6 Global Erythropoietin Drugs Market Analysis, by Drug Type
7 Global Erythropoietin Drugs Market Analysis, by Drug Type
8 Global Erythropoietin Drugs Market Analysis, by Drug Application
9 Global Erythropoietin Drugs Market Analysis, by Region
10 North America Erythropoietin Drugs Market Analysis
11 Europe Erythropoietin Drugs Market Analysis
12 Asia Pacific Erythropoietin Drugs Market Analysis
13 Asia Pacific Erythropoietin Drugs Market Analysis
14 Middle East & Africa Erythropoietin Drugs Market Analysis

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/1856